As our interest to use cyclodextrin in genetherapy as superior drugdelivery tools continue, we welcome papers like this, where cationic CD polymers are used for nucleotide formulation.
Leonard Wiebe and coworkers from University of Alberta development a carrier designed to effect selective transmembrane internalization of nucleotides via the asialoglycoprotein receptor.
Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study
In this work form University of Southern California blocking viral attachment and entry at the nasal airway using a cyclodextrin-based formulation is presented, so that a preventative therapy can be developed to reduce viral infection at the site of entry. After screening several CDs, hydroxypropyl beta-cyclodextrin (HPBCD) and hydroxypropyl gamma-cyclodextrin (HPGCD) were then further evaluated for antiviral effects using SARS-CoV-2 pseudotypes. Intranasal pre-treatment with HPBCD-based formulations reduced viral load and inflammatory signaling in the lung.
In vitro efficacy studies were further conducted using lentiviruses, murine hepatitis virus (MHV), and influenza A virus subtype H1N1. These findings suggest HPBCD may be used as an agnostic barrier against transmissible pathogens, including but not limited to SARS-CoV-2.
today’s cyclodextrin:
I am proud to share this new patent from Cyclarity Therapeutics not only because of the fantastic chemistry and excellent drug development but also as CarboHyde CSO Milo Malanga is among the inventors!
Cyclodextrin dimers are used to target 7-ketocholesterol, eventually to reverse atherosclerotic plaques.
Check out for more info: Espacenet – US2024043661A1
Congratulation to Milo and the geat team at Cyclarity!